ABSTRACT
Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.
Subject(s)
Graft vs Leukemia Effect/immunology , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid/therapy , Membrane Glycoproteins/immunology , T-Lymphocytes, Cytotoxic/cytology , T-Lymphocytes, Cytotoxic/immunology , Antigens, Neoplasm/immunology , Cell Line , Dendritic Cells/cytology , Dendritic Cells/immunology , Epitope Mapping , Histocompatibility Testing , Humans , Immunophenotyping , Leukemia, Myeloid/immunology , Leukocyte Elastase/immunology , Myeloblastin/immunology , Peptide Fragments/immunology , Recurrence , Tissue Donors , Transplantation, Homologous , WT1 Proteins/immunologyABSTRACT
Methods to improve plasmid-mediated transgene expression are needed for gene medicine and gene vaccination applications. To maintain a low risk of insertional mutagenesis-mediated gene activation, expression-augmenting sequences would ideally function to improve transgene expression from transiently transfected intact plasmid, but not from spurious genomically integrated vectors. We report herein the development of potent minimal, antibiotic-free, high-manufacturing-yield mammalian expression vectors incorporating rationally designed additive combinations of expression enhancers. The SV40 72 bp enhancer incorporated upstream of the cytomegalovirus (CMV) enhancer selectively improved extrachromosomal transgene expression. The human T-lymphotropic virus type I (HTLV-I) R region, incorporated downstream of the CMV promoter, dramatically increased mRNA translation efficiency, but not overall mRNA levels, after transient transfection. A similar mRNA translation efficiency increase was observed with plasmid vectors incorporating and expressing the protein kinase R-inhibiting adenoviral viral associated (VA)1 RNA. Strikingly, HTLV-I R and VA1 did not increase transgene expression or mRNA translation efficiency from plasmid DNA after genomic integration. The vector platform, when combined with electroporation delivery, further increased transgene expression and improved HIV-1 gp120 DNA vaccine-induced neutralizing antibody titers in rabbits. These antibiotic-free vectors incorporating transient expression enhancers are safer, more potent alternatives to improve transgene expression for DNA therapy or vaccination.
Subject(s)
Gene Expression , Gene Transfer Techniques , Genetic Vectors , Plasmids , Transgenes , Animals , Cell Line , Humans , RNA, Messenger/metabolism , eIF-2 Kinase/antagonists & inhibitorsABSTRACT
OBJECTIVE: The aim of this study was to differentiate between the peripheral and central analgesic and antihyperalgesic properties of systemic procaine hydrochloride in standardized human pain models. METHOD: Subcutaneous injections of either 150 mg procaine hydrochloride or saline solution were administered at intervals of 2 weeks on a randomized and double blind basis. During the 90-min infusion and subsequent 60-min monitoring periods, touch sensitivity was determined and in addition two experimental hyperalgesic models were analyzed. RESULTS: While touch sensitivity was not affected by procaine hydrochloride, development of primary mechanical hyperalgesia was significantly reduced. CONCLUSION: The concentration of procaine hydrochloride used in our experiment elicited peripheral antihyperalgesic effects without central venous side effects. These results can account for the clinical effect of low-dose procaine hydrochloride in pain conditions exhibiting pronounced hyperalgesia.